The study also investigates treatment-specific endocrine side effects based on immunohistochemical stratification, with a focus on human epidermal growth factor receptor 2 (HER2) expression as the optimal treatment strategy for HER2-positive tumours, particularly in the context of endocrine therapy, is not fully elucidated. This evidence concerns the gene ERBB2 and neoplasm.